Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (primate/human) |
Target | CD80 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
![]() ![]() |
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma.[1] As of September 2009[update], it is undergoing Phase III clinical trials.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[3]
| |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (initiation) |
| ||||||||||||||
Intracellular (reception) |
| ||||||||||||||
Extracellular |
| ||||||||||||||
Unsorted |
|
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
![]() | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |